Kerri Schellenberg

Dr. Kerri Schellenberg

Principal Applicant

Neuromuscular Neurologist at University of Saskatchewan | Associate Professor at University of Saskatchewan

Medical Director of the ALS/MND clinic and the Royal University Hospital EMG lab | co-chair of the Canadian ALS research network


NMD4C Involvement: Pillar 2: Clinical Research, Theme 2: Equity, Diversity, Inclusion, and Indigeneity (EDII), Theme 5: Open Science

Email Kerri

Research Interests: Neuromuscular, ALS, Spinobulbar Muscular Atrophy (SBMA), Motor Neuron Disease, Spinal Muscular Atrophy (SMA)

Google Scholar profile

Biography

Dr. Kerri Schellenberg, MD, FRCPC, MMedEd is a Neuromuscular Neurologist and Associate Professor at the University of Saskatchewan. She is the Medical Director of the ALS/MND clinic and the Medical Director of the Royal University Hospital EMG lab. She serves as Competency Committee Chair for the neurology program. Her research primarily focuses on motor neuron diseases (ALS, SBMA, and SMA), and includes publications in clinical aspects of neuromuscular disease. She has served as local PI for international treatment trials in ALS, local PI for the Canadian Neuromuscular Disease registry, contributed to Canadian ALS Best Practice Recommendations, and has ongoing grants and projects with local and national research partners to further understanding of neuromuscular disease.     

She completed her medical studies at the University of Saskatchewan, a Neurology residency at the University of Alberta, followed by a Neuromuscular fellowship at Duke University in North Carolina.  Dr. Schellenberg was the recipient of the Betty Norman Research Fellowship Award from the ALS Society of Canada to pursue an ALS fellowship at the University of Alberta.  She has a Masters of Medical Education from the University of Dundee.


Recent Publications

Schellenberg, KL, Osman, H, Masnata, M, Hicks, R, Kagan, C, Stosic, A et al.. Implementation of a neuromuscular clinical trial network: a rare disease model for enhancing clinical trial readiness, capacity, and access in Canada. Orphanet J Rare Dis. 2026. PMID:42192450

Schellenberg, KL, Nataraj, R. Reviewer Comment on Li et al. "Nocturnal Hypoxia and Sleep-Disordered Breathing as Potential Early Biomarkers of Respiratory Progression in Mild ALS". Can J Neurol Sci. 2026. 1 PMID:41906714

Schellenberg, KL, Caspar-Bell, G, Ellis, C, Johnston, W, King, A, King, M et al.. [Not Available]. CMAJ. 2026.198 (3)E96-E111 PMID:41587800

Breiner, A, Schellenberg, KL, Shoesmith, C. [Not Available]. CMAJ. 2025.197 (36)E1211-E1213 PMID:41145189

Breiner, A, Schellenberg, KL, Shoesmith, C. Integrating genetic testing into management of all patients with amyotrophic lateral sclerosis: a critical juncture. CMAJ. 2025.197 (31)E1006-E1007 PMID:40983390

See more on PubMed